- The approval is based on two P-III studies assessing the combination of dapagliflozin (5mg, 10mg) ,saxagliptin (5mg) and metformin in patients with inadequately controlled Type-2 diabetes for 24wks.
- The collective studies result demonstrated a reduction in HbA1c (average blood glucose levels) & increment in no. pf patients achieving HbA1c <7%
- Qternmet XR (qd, PO) is a triple combination therapy consisting of dapagliflozin (sodium‑glucose cotransporter-2 (SGLT-2) inhibitor), saxagliptin (dipeptidyl peptidase‑4 (DPP‑4) inhibitor) & metformin hydrochloride , approved by FDA as an adjunct to diet and exercise for improving glycaemic control in adults with T-2D
Click here to read full press release/ article | Ref: AstraZeneca | Image: Simply Wall